The creative studio and 01Booster’s four-month joint venture will help grow the entrepreneurial ecosystem in the Japanese city of Fukushima and environs.

Sidecar Health, which offers health insurance billed through a debit card, attracted Comcast Ventures to a round that brought its funding total to $40m.

Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.

Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to 6 Dimensions Capital.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

CSPC returned for the anti-tumour therapy developer's series B round having backed its $147m series A early last year.

Merck Global Health Innovation Fund and existing investor Cedars-Sinai took part in a $17m round for the blood collection technology provider.

The messenger RNA vaccine and drug developer's latest round includes a $171m investment by strategic partner GlaxoSmithKline.

GV had led an oversubscribed series D round for the gene therapy developer that also featured Illumina Ventures and SoftBank Vision Fund II.

Pfizer and Chiesi-backed genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.